Literature DB >> 12845486

Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT.

Nicolas Aide1, Olivier Cappele, Philippe Bottet, Henri Bensadoun, Armelle Regeasse, François Comoz, Franck Sobrio, Gérard Bouvard, Denis Agostini.   

Abstract

The purpose of this study was to assess the efficiency of fluorine-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the characterisation and primary staging of suspicious renal masses, in comparison with computed tomography, the current standard imaging modality. Fifty-three FDG PET studies were performed within the framework of a prospective study: 35 for both characterisation and staging of a suspicious mass, and 18 for staging early after surgical removal of a renal cancer. In the characterisation of renal masses, a high rate of false negative results was observed, leading to a sensitivity, specificity and accuracy of 47%, 80% and 51% respectively, versus 97%, 0/5 and 83% respectively for CT. FDG PET detected all the sites of distant metastasis revealed by CT, as well as eight additional metastatic sites, leading to an accuracy of 94% versus 89% for CT. However, 36/53 patients (68%) did not have any distant metastasis on either CT or on PET. All but one of these patients had a low Fuhrman histological grade and a limited local stage (< or =pT2). We conclude that FDG PET does not offer any advantage over CT for the characterisation of renal masses but that it appears to be an efficient tool for the detection of distant metastasis in renal cancer. However, our data suggest that a selection process could be implemented to determine which patients should undergo PET. FDG PET could be performed in the event of a solitary metastasis or doubtful images on CT. Selection could also be based on adverse histological findings from nephrectomy specimens in order to perform staging early after nephrectomy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845486     DOI: 10.1007/s00259-003-1211-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  17 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Guidelines on renal cell cancer.

Authors:  G Mickisch; J Carballido; S Hellsten; H Schulze; H Mensink
Journal:  Eur Urol       Date:  2001-09       Impact factor: 20.096

3.  In vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma.

Authors:  F Montravers; C Rousseau; J D Doublet; B Gattengo; S Allard; P Fouret; J F Bernaudin; P Thibault; J N Talbot
Journal:  Nucl Med Commun       Date:  1998-10       Impact factor: 1.690

4.  FDG PET characterization of renal masses: preliminary experience.

Authors:  M A Goldberg; W W Mayo-Smith; N Papanicolaou; A J Fischman; M J Lee
Journal:  Clin Radiol       Date:  1997-07       Impact factor: 2.350

5.  Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer.

Authors:  Hideshi Miyakita; Masatosi Tokunaga; Hajime Onda; Yukio Usui; Hidechika Kinoshita; Nobuo Kawamura; Seiei Yasuda
Journal:  Int J Urol       Date:  2002-01       Impact factor: 3.369

6.  Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients.

Authors:  Andrea Minervini; Leon Lilas; Riccardo Minervini; Cesare Selli
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

7.  Observations on the growth rate of renal cell carcinoma.

Authors:  N Fujimoto; A Sugita; Y Terasawa; M Kato
Journal:  Int J Urol       Date:  1995-05       Impact factor: 3.369

8.  Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases.

Authors:  Vincenzo Ficarra; Rita Righetti; Stefania Pilloni; Antonio D'amico; Nicola Maffei; Giovanni Novella; Luisa Zanolla; Gianni Malossini; Gaetano Mobilio
Journal:  Eur Urol       Date:  2002-02       Impact factor: 20.096

9.  Small renal cell carcinomas: resolving a diagnostic dilemma.

Authors:  M A Amendola; R L Bree; H M Pollack; I R Francis; G M Glazer; S Z Jafri; J E Tomaszewski
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  54 in total

Review 1.  Imaging of advanced renal cell carcinoma.

Authors:  Ullrich G Mueller-Lisse; Ulrike L Mueller-Lisse
Journal:  World J Urol       Date:  2010-05-11       Impact factor: 4.226

2.  Renal oncocytoma on 1-11C acetate positron emission tomography: Case report and literature review.

Authors:  Jabi Shriki; Venkatesh Murthy; Jeffrey Brown
Journal:  Mol Imaging Biol       Date:  2006 Jul-Aug       Impact factor: 3.488

3.  2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses.

Authors:  Rakesh Kumar; Anil Chauhan; Paras Lakhani; Yan Xiu; Hongming Zhuang; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

Review 4.  Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.

Authors:  Vidhya Karivedu; Amit L Jain; Thomas J Eluvathingal; Abhinav Sidana
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

Review 5.  Advances in medical imaging for the diagnosis and management of common genitourinary cancers.

Authors:  Mohammad H Bagheri; Mark A Ahlman; Liza Lindenberg; Baris Turkbey; Jeffrey Lin; Ali Cahid Civelek; Ashkan A Malayeri; Piyush K Agarwal; Peter L Choyke; Les R Folio; Andrea B Apolo
Journal:  Urol Oncol       Date:  2017-05-12       Impact factor: 3.498

Review 6.  Targeted therapies in renal cell cancer: recent developments in imaging.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Journal:  Target Oncol       Date:  2010-07-14       Impact factor: 4.493

7.  Recent developments in kidney cancer.

Authors:  Michael J Leveridge; Michael A S Jewett
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

Review 8.  Functional imaging of renal cell carcinoma.

Authors:  Nathan Lawrentschuk; Ian D Davis; Damien M Bolton; Andrew M Scott
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

9.  FDG PET or PET/CT in evaluation of renal angiomyolipoma.

Authors:  Chun-Yi Lin; Hui-Yi Chen; Hueisch-Jy Ding; Kuo-Yang Yen; Chia-Hung Kao
Journal:  Korean J Radiol       Date:  2013-02-22       Impact factor: 3.500

10.  Evaluation of cancer treatment in the abdomen: Trends and advances.

Authors:  Silanath Peungjesada; Hubert H Chuang; Srinivasa R Prasad; Haesun Choi; Evelyne M Loyer; Yulia Bronstein
Journal:  World J Radiol       Date:  2013-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.